Company
Headquarters: London, United Kingdom
Founded: 1978
Employees: 8,700
CEO: Mr. Sigurdur Oli Olafsson Ph.D.
£4.63 Billion
GBP as of Jan. 1, 2025
US$5.80 Billion
Company | Market Cap (USD) |
---|---|
Lilly | $689.42 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $487.54 B |
Johnson & Johnson | $353.05 B |
AbbVie | $301.60 B |
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment develops, manufactures, and sells generic injectable products primarily for use in hospitals. The Generics segment develops, manufactures, and sells oral and other non-injectable generic products for the retail market. The Branded segment develops, manufactures, markets, and sells branded generics and in-licensed products to retail and hospital markets. The company offers its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, anesthetic, sedative, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Last Financial Reports Date | June 30, 2019 |
Revenue TTM | £2.46 B |
EBITDA | £786.0 M |
Gross Profit TTM | £1.18 B |
Profit Margin | 9.45% |
Operating Margin | 25.62% |
Quarterly Revenue Growth | 10.00% |
Hikma Pharmaceuticals plc has the following listings and related stock indices.
Stock: LSE: HIK wb_incandescent
Stock: FSX: H5P wb_incandescent
AmoclanPrografSuprax
Founder(s): Samih Darwazah
Said Darwazah (chairperson) Siggi Olafsson (CEO)